Last reviewed · How we verify
Raltegravir and Atazanavir
Raltegravir and Atazanavir is a Antiretroviral combination (integrase inhibitor + protease inhibitor) Small molecule drug developed by Peter J. Ruane, M.D., Inc.. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults.
This combination inhibits HIV replication by blocking integrase (raltegravir) and protease (atazanavir), preventing viral DNA integration and polyprotein processing.
This combination inhibits HIV replication by blocking integrase (raltegravir) and protease (atazanavir), preventing viral DNA integration and polyprotein processing. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | Raltegravir and Atazanavir |
|---|---|
| Sponsor | Peter J. Ruane, M.D., Inc. |
| Drug class | Antiretroviral combination (integrase inhibitor + protease inhibitor) |
| Target | HIV integrase and HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the viral genome from integrating into host chromosomal DNA. Atazanavir is a protease inhibitor (PI) that blocks HIV protease, preventing cleavage of viral polyproteins into functional enzymes and structural proteins. Together, they provide dual-mechanism antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Nausea
- Diarrhea
- Headache
- Hyperbilirubinemia (atazanavir-related)
- Rash
- Elevated transaminases
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Population Pharmacokinetics of Antiretroviral in Children
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- Kuwa Free! - Live Free! (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raltegravir and Atazanavir CI brief — competitive landscape report
- Raltegravir and Atazanavir updates RSS · CI watch RSS
- Peter J. Ruane, M.D., Inc. portfolio CI
Frequently asked questions about Raltegravir and Atazanavir
What is Raltegravir and Atazanavir?
How does Raltegravir and Atazanavir work?
What is Raltegravir and Atazanavir used for?
Who makes Raltegravir and Atazanavir?
What drug class is Raltegravir and Atazanavir in?
What development phase is Raltegravir and Atazanavir in?
What are the side effects of Raltegravir and Atazanavir?
What does Raltegravir and Atazanavir target?
Related
- Drug class: All Antiretroviral combination (integrase inhibitor + protease inhibitor) drugs
- Target: All drugs targeting HIV integrase and HIV protease
- Manufacturer: Peter J. Ruane, M.D., Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Compare: Raltegravir and Atazanavir vs similar drugs
- Pricing: Raltegravir and Atazanavir cost, discount & access